JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential
Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paulson & Co John Paulson | 2,099,523 | $695,425,003 | +3% | 39.81% |
| 2. | VenBio Select Advisor Kurt Von Emster | 2,022,222 | $669,820,593 | -1% | 10.46% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,974,590 | $654,043,446 | 7.24% | |
| 4. | Holocene Advisors Brandon Haley | 390,545 | $129,360,220 | 0.38% | |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 317,433 | $105,143,333 | +3% | 0.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $229.86 | 3,960 | $910,264.21 | 1,793,403 | 2023-12-14 | Filing | |
| $229.86 | 316 | $72,637.25 | 185,979 | 2023-12-14 | Filing | |
| $228.79 | 2,204 | $504,251.62 | 1,789,443 | 2023-12-14 | Filing | |
| $228.79 | 176 | $40,266.92 | 185,663 | 2023-12-14 | Filing | |
| $227.86 | 11,602 | $2,643,596.91 | 1,787,239 | 2023-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $330.23 | 75 | $24,766.88 | 350,076 | 2025-03-13 | Filing | |
| $329.86 | 967 | $318,974.72 | 350,151 | 2025-03-13 | Filing | |
| $328.68 | 400 | $131,472.48 | 351,118 | 2025-03-13 | Filing | |
| $327.63 | 1,000 | $327,626.80 | 351,518 | 2025-03-13 | Filing | |
| $325.63 | 800 | $260,501.04 | 352,518 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 701 | $209,508 | 0% | |
| 2. | 324 | $99,983 | 0.02% | |
| 3. | 272 | $82,318 | 0% | |
| 4. | 233 | $70,515 | 0% | |
| 5. | 91 | $27,540 | 0% |
News See All
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Billionaire Nicholas J. Pritzker's 8 Stocks with Huge Upside Potential
Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners, a San Francisco-based venture capital firm established in 2013.
Billionaire John Paulson's 10 Stocks with Huge Upside Potential
John Alfred Paulson is an American billionaire hedge fund manager who founded Paulson & Co. in 1994. It is a New York-based fund management firm that specializes in private equity and hedge funds.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript February 26, 2025Madrigal Pharmaceuticals, Inc. beats earnings expectations.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Billionaire Hedge Funds
